Sanofi India Q1 PAT up 63.4% at Rs238.4cr on exceptional gain from sale of distribution business of Soframycin, Sofradex

27 Apr 2022 , 10:36 PM

Sanofi India Ltd reported -2.50% lower sales revenues yoy for the Mar-22 quarter on consolidated basis at Rs707cr. On a sequential basis, revenues were higher for the quarter by 2.78%.

Sanofi India follows the calendar year so Mar-22 is the first quarter for them.

In the meeting held on 15-November, the board of directors have approved the transfer of tangible and intangible assets related to the distribution business of Soframycin and Sofradex to Encube Ethicals Private Limited. The transaction concluded in January 2022.

The consolidated net profit for Q4 was up 63.40% at Rs238.40cr while it was up on a sequential basis by 163.72%.

The sharp spike in profits is on account of an exceptional gain of Rs.118.10cr in the fourth quarter on account the sale of distribution business of Soframycin and Sofradex.

The entire consideration has been received by the company and the gain has been booked as an exceptional gain. Net margins stood at 33.72% in Mar-22 quarter compared to 20.12% in Mar-21. NPM was higher sequentially compared to 13.14% in Q3.

Financial highlights for Mar-22 compared yoy and sequentially

	Sanofi India
Rs in Crore	Mar-22	Mar-21	YOY	Dec-21	QOQ
Total Income (Rs cr)	₹ 707.00	₹ 725.10	-2.50%	₹ 687.90	2.78%
Net Profit (Rs cr)	₹ 238.40	₹ 145.90	63.40%	₹ 90.40	163.72%
Diluted EPS (Rs)	₹ 103.51	₹ 63.35		₹ 39.25
Net Margins	33.72%	20.12%		13.14%